Viking Therapeutics Inc Stock

Demand for GLP-1 drugs is soaring. Thanks to recent breakthroughs, medicines in this category are expanding their addressable markets and treating conditions such as obstructive sleep apnea (OSA)

Shares in Viking Therapeutics (NASDAQ: VKTX) declined by 18.6% in July, according to data from S&P Global Market Intelligence. The decline came during a slow month for newsflow in its pipeline, as

Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, have declined by 46% over the past two years. There are several reasons for this. First, longtime shareholders decided to

The human appetite has more than one off switch, and drugmakers like Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are doing their darndest to identify and develop a medicine to target every

Following an excellent run in June, when the stock rose by more than 19%, Viking Therapeutics (NASDAQ: VKTX) stock recently dipped, potentially creating a buying opportunity for an exciting growth

Over the past five years, Viking Therapeutics' (NASDAQ: VKTX) shares have climbed more than 500% as the company has made significant progress with its leading pipeline candidates. The clinical-stage

Viking Therapeutics (NASDAQ: VKTX) may be one of biotech's most tempting buyout targets, thanks to its weight loss drug pipeline and massive obesity market opportunity. But the stock also carries

Genetic engineering and weight-loss innovation have become focal points for modern healthcare investors. Choosing between CRISPR Therapeutics AG (NASDAQ:CRSP) and Viking Therapeutics (NASDAQ:VKTX)

Investing in biotechnology requires a balance between groundbreaking scientific innovation and the realities of clinical development. Choosing between CRISPR Therapeutics (NASDAQ:CRSP) and Viking

The short, but glib, answer to the headline question posed for Viking Therapeutics (NASDAQ: VKTX) investors is "no," because the likelihood is that the $4.6 billion market cap company will be bought

Viking Therapeutics (NASDAQ: VKTX) is a challenger in the obesity drugs gold rush, trailing Eli Lilly and Novo Nordisk as they rake in cash from their highly successful medicines. Viking's lead

Viking Therapeutics (NASDAQ: VKTX) is one of the hopefuls in a very exciting pharmaceutical and biotech space right now: the weight loss drug market. Today, pharma giants Eli Lilly and Novo Nordisk

Viking Therapeutics (NASDAQ: VKTX) stock rose by 19.2% in June, according to data from S&P Global Market Intelligence. The move comes as optimism rises over the company's pipeline development

Shares of Viking Therapeutics (NASDAQ: VKTX) have climbed by 27% over the past month. The drugmaker is a serious candidate to make waves in the large and growing anti-obesity drug market. With

High-stakes clinical trials define the 2026 landscape for Dyne Therapeutics (NASDAQ:DYN) and Viking Therapeutics (NASDAQ:VKTX). Both firms seek to revolutionize patient care while navigating the

GLP-1 drugs are proving helpful for many conditions, not just weight loss. In studies, they have shown they can reduce cardiovascular risk, sleep apnea, and even curb addictions. They have the

Shares of Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, have moved in exactly the wrong direction this year, down 8% to date. However, the drugmaker has important catalysts on the